Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377795 | 0.89 | F10 (0.44) | F10POLBGAAHPGDSMN1; SMN2 | |
| SCHEMBL5467839 | 0.88 | F10 (0.39) | F10HTR7GAA | |
| SCHEMBL4508161 | 0.84 | F10 (0.35) | F10HDAC8HDAC6 | |
| SCHEMBL5380004 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL5371113 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL5386312 | 0.81 | F10 (0.39) | F10 | |
| SCHEMBL5459404 | 0.81 | NAMPT (0.45) | F10 | |
| SCHEMBL5380531 | 0.80 | F10 (0.38) | F10 | |
| SCHEMBL6359962 | 0.80 | KDM4E (0.36) | F10 | |
| SCHEMBL5379823 | 0.80 | F10 (0.38) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | SERPINE1, PLAT, SERPINC1 | F10 16/4885GPR119 1679/4885POLB 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.